We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of diabetes and metformin use on prostate cancer.
- Authors
Taussky, Daniel; Delouya, Guila
- Abstract
Up to date, there are only few published prospective studies on metformin and prostate cancer (Pca) such as the Swiss phase 2 study in chemotherapy-naive castration-resistant patients (CRPC). They found that in the 254 patients (3.8%) who had PCa and diabetes, no differences were seen in prostate cancer-specific survival between men with or without type 2 Diabetes. In a study from Finland, men using antidiabetic drugs had a lower overall PCa risk, and metformin decreased the PCa risk in a dose-dependent manner [[5]].
- Subjects
PROSTATE cancer; CASTRATION-resistant prostate cancer; METFORMIN; TYPE 2 diabetes; ANTINEOPLASTIC agents
- Publication
Scandinavian Journal of Urology, 2020, Vol 54, Issue 6, p508
- ISSN
2168-1805
- Publication type
Editorial
- DOI
10.1080/21681805.2020.1806355